Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience

Internal Medicine Journal

Volumn 41, Issue 4, 2011, Pages 299-307

  Martin, J H ^a   Deacon, C F ^c   Gorrell, M D ^b   Prins, J B ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

DPP4; GIP; GLP 1; Incretin; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIRAGLUTIDE; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

GASTROINTESTINAL DISEASE; GLUCAGON RELEASE; HUMAN; METABOLIC DISORDER; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SKIN DEFECT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EATING; HUMANS; INCRETINS; INSULIN-SECRETING CELLS; RECEPTORS, GLUCAGON;

EID: 79955013099     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02439.x     Document Type: Review

References (71)

1. Modlin I, Kidd M. Ernest Starling and the discovery of secretin. J Clin Gastroenterol 2001; 32: 187-92.
2. La Barre J. Sur les possibilites d'un traitement du diabete par l'incretine. Bull Acad R Med Belg 1932; 12: 620-34.
3. Elrick H, Stimmler L, Hlad C, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Invest 1964; 242: 1076-82.
4. Creutzfeldt W. The incretin concept today. Diabetalogia 1979; 16: 75-85.
5. Dupre J, Ross S, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826-8.
6. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 716-18.
7. Vilsboll T, Karup K, Madsbad S, Holst J. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Reg Pept 2003; 114: 115-21.
8. Baggio L, Drucker D. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-57.
9. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-7.
10. Deacon CF, Nauck MA, Meier J, Hucking K, Holst J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85: 3575-81.
11. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005; 128: 117-24.
12. Elahi D, Egan J, Shannon R, Meneilly G, Khatri A, Habener J etal. GLP-1 (9-36) Amide, Cleavage Product of GLP-1 (7-36) Amide, Is a Glucoregulatory Peptide. Obesity 2008; 16: 1501-9.
13. Meier JJ, Gethmann A, Nauck MA, Götze O, Schmitz F, Deacon CF etal. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab 2006; 290: E1118-23.
14. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146-51.
15. Ban K, Noyan-Ashraf M, Hoefer J, Bolz S, Drucker D, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-50.
16. Nikolaidis L, Dariush Elahi D, Shen Y-T SR. Active Metabolite of GLP-1 Mediates Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs with Dilated Cardiomyopathy. Am J Physiol Heart Circ Physiol 2005; 289: H2401-8.
17. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D etal. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53: 654-62.
18. Linnebjerg H, Kothare P, Park S, Mace K, Reddy S, Mitchell M etal. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 312-27.
19. Alcántaraa A, Moralesa M, Delgadoa E, López-Delgadoa M, Clementea F, Luquea M etal. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys 1997; 341: 1-7.
20. Syme C, Zhang L, Bisello A. Caveolin regulates cellular trafficking and function of the glucagon-like peptide 1 receptor. Mol Endocrinol 2006; 20: 3400-11.
21. Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, Takahashi N etal. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem 2007; 282: 10117-31.
22. MacDonald P, El-Kholy W, Riedel M, Salapatek A, Light P, Wheeler M. The multiple actions of GLp-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002; 51 (Suppl 3): S434-42.
23. Orskov C, Poulsen S, Moller M, Holst J. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996; 45: 832-5.
24. Larsen P, Tang-Christensen M, Holst J, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997; 77: 257-70.
25. Lamari Y, Boissard C, Moukhtar M, Jullienne A, Rosselin G, Garel J-M. Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett 1996; 393: 248-52.
26. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N etal. The murine glucagon-like peptide-1 receptor is essential for control of bone resportion. Endocrinology 2008; 149: 574-9.
27. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48: 736-43.
28. Nuche-Berenguer B, Portal-Núñez S, Moreno P, González N, Acitores A, López-Herradón A etal. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol 2010; 225: 585-92.
29. de Heer J, Rasmussen C, Coy D, Holst J. Glucagon-like peptide-1, but not glucose-dependent insulinotropc peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfised rat pancreas. Diabetologia 2008; 51: 2263-70.
30. Meier J, Gallwitz B, Siepmann N, Holst J, Deacon C, Schmidt WE etal. Gastic inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003; 46: 798-801.
31. Asmar M, Tangaa W, Madsbad S, Hare K, Astrup A, Flint A etal. On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. Am J Physiol Endocrinol Metab 2010; 298: E614-21.
32. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54: 10-18.
33. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52: 380-6.
34. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetalogia 2002; 45: 1111-9.
35. Deacon C, Nauck MA, Toft-Neilsen M, Pridal L, Willms B, Holst J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-31.
36. Kirby MS, Yu DMT, O'Connor SP, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 2010; 118: 31-41.
37. Yu DMT, Yao T-W, Chowdhury S, Nadvi NA, Osborne B, McCaughan GW etal. The Dipeptidyl Peptidase IV family in cancer and cell biology. FEBS Journal 2010; 277: 1126-44.
38. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. Systematic review and meta-analysis. JAMA 2007; 298: 194-206.
39. Williams-Herman D, Engel S, Round E, Johnson J, Golm G, Guo H etal. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10, 246 patients with type 2 diabetes. BMC Endocr Disord 2010; 10: [Epub ahead of print] DOI: 10.1186/1472-6823-10-7
40. Ligueros-Saylan M, Foley J, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010; 12: 495-509.
41. Zaruba M, Theiss H, Vallaster M, Mehl U, Brunner S, David R etal. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009; 4: 313-23.
42. Schuppan D, Gorrell M, Klein T, Mark M, Afdhal N. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 2010; 30: 795-808.
43. Meier J. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 2008; 51: 703-13.
44. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60: 1454-70.
45. Eng J, Kleinman W, Singh L, Singh G, Raufman J. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-5.
46. Thum A, Hupe-Sodmann K, Göke R, Voigt K, Göke B, McGregor G. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes 2002; 110: 113-18.
47. Simonsen L, Holst J, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 2006; 49: 706-12.
48. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm 2005; 62: 173-81.
49. Kolterman O, Buse J, Fineman M, Gaines E, Heintz S, Bicsak T etal. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-9.
50. Drucker D, Buse JB, Taylor K, Kendall D, Trautmann M, Zhuang D. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-50.
51. Agerso H, Jensen L, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetalogia 2002; 45: 195-202.
52. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010; 26: 540-49.
53. Buse J, Rosenstock J, Sesti G, Schmidt W, Montanya E, Brett J etal. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
54. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P etal. for the DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus saxagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-9.
55. Pratley RE, Nauck MA, Bailey T, Montanya E, Cuddihy R, Filetti S etal. 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-56.
56. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K etal. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010; 33: 1509-15.
57. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B etal. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-248.
58. Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 2009; 5: 199-211.
59. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S etal. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-55.
60. Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K etal. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-43.
61. Baggio L, Holland D, Wither J, Drucker D. Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice. Diabetes 2006; 55: 1562-70.
62. Dore D, Seeger J, Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-27.
63. Engel SS, Williams-Herman DE, Golm GT, Clay RJ, Machotka SV, Kaufman KD etal. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010; 64: 984-90.
64. US Food and Drug Administration. 2009 [cited 2009 April 27] Available from:
65. Crespel A, De Boisvilliers F, Gros L, Kervran A. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology 1996; 137: 3674-80.
66. Knudsen LB, Madsen L, Andersen S, Almholt K, de Boer A, Drucker D etal. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151: 1473-86.
67. Product Information - Januvia sitagliptin. 2007 Whitehouse Station N, Merck and Co, Inc.
68. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus C, Holcombe J etal. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3years. Curr Med Res Opin 2008; 24: 275-86.
69. Zinman B, Buse J, Falahati A, Moses A, Gough S. Liraglutide more effectively achieves a composite endpoint for A1c, SBP and weight change than other diabetes therapies. Diabetes 2009; 58 (Suppl 1): A143. 537-P.
70. Frederich R, Alexander JH, Fiedorek F, Donovan M, Berglind N, Harris S etal. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122: 16-27.
71. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD etal. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100: 824-9.